Hyderabad: In the first example of collaboration in the pharmaceutical sector, five majors Pharmacy India – Cipla Ltd., Dr.
Reddy’s Laboratories Ltd, Sun Pharmaceutical Industries Ltd, Torrent Pharmaceuticals Ltd – has joined hands to conduct anti-viral clinical trials oral investigations.
Molnupiravir medicine for Covid-19 treatment is light in outpatient arrangements in India.
Five players have signed a collaboration agreement, as part of where they will sponsor, supervise, and monitor clinical trials in India.
Following the approval of the clinical protocol protocol given by the drug controller General India (DCGI), the trial will be carried out for the treatment of covid-19 light in the arrangement of outpatient.
The trial is expected to occur between June and September this year throughout India with 1,200 patients recruitment.
“In accordance with the direction of the Subject Expert Committee (SEC) the Standard Control Organization Center Medicine, Dr.
Reddy will conduct clinical trials using their products and four other pharmaceutical companies will be asked to show the equality of their products to the product.
Used by Dr.
Reddy in his clinical trial , “said the pharmaceutical company in a joint statement.
“Such collaboration for clinical trials is the first of its kind in the Indian Pharma industry, and will aim to investigate other treatment lines in collective battles against Covid-19 pandemics.
In the success of clinical trial settlement, each company will independently approach regulatory authorities for approval To produce and supply Molnupiravir for Covid-19 treatment in India, “said a joint statement.
The five companies have, between March and April this year, individually signing a non-exclusive voluntary license agreement with Merck Sharpe DoHME (MSD) for the manufacture and supply of Molnupiravir to the Indian market and more than 100 low-income and medium-sized countries (LMICs).